Halozyme Raises $13.9M

San Diego-based Halozyme Therapeutics announced that it has received $13.9M in a private placement. The company, which is listed on the OTC bulletin board, did not disclose the investors in the PIPE. The placement agent was SG Cowen & Co. The company is backed by Cimarron Biomedical, Colt Ventures, Grove Capital, and Richie Capital, among others. Halozyme is developing and commercializing recombinant human enzymes for infertility, opthalmology, and oncology. More information »